Trends in Hypertensive Disorders of Pregnancy in the United States From 1989 to 2020

Bruno, Ann M.; Allshouse, Amanda A.; Metz, Torri D.; Theilen, Lauren

doi:10.1097/aog.0000000000004824

Cited by 24 publications

(16 citation statements)

References 6 publications

(9 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We have found, as others have reported, 4 that the rate of HDP continues to rise, perhaps reflecting demographic trends (eg, obesity and age). Consistent with prior literature, 5 our finding of a lower rate of HDP among patients induced at 39 weeks of gestation, perhaps due to a greater percentage of low-risk patients undergoing non–medically indicated inductions post-ARRIVE, suggests that, as the number of pregnant patients with HDP rises, the relative advantage of induction may rise similarly.…”

Section: Discussionsupporting

confidence: 84%

“…1 We have shown previously that obstetric practices changed to reflect a nationwide response to the lowered risk of cesarean delivery reported in the ARRIVE trial. 2,3 Given recent data demonstrating an overall increase in HDP, 4 we sought to confirm the ARRIVE trial's conclusion by using a national data set to assess trends in HDP among nulliparous patients in the 2 years post-ARRIVE.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Changes in Rates of Hypertensive Disorders of Pregnancy Among Nulliparous Patients After the ARRIVE (A Randomized Trial of Induction Versus Expectant Management) Trial

Futterman

Gilroy

Silver

et al. 2023

Obstetrics &Amp; Gynecology

View full text Add to dashboard Cite

The ARRIVE (A Randomized Trial of Induction Versus Expectant Management) trial demonstrated lower rates of hypertensive disorders of pregnancy (HDP) among low-risk nulliparous patients undergoing labor induction at 39 weeks of gestation. We conducted a population-based cohort study in which we evaluated the association between the routinization of 39-week induction and the rate of HDP by comparing rates before and after the ARRIVE trial publication, using the National Vital Statistics System. Logistic regression models were used to project what the HDP rate would have been based on trends seen pre-ARRIVE. Despite an overall increase in the rate of HDP from pre-ARRIVE to post-ARRIVE (4.9% pre vs 6.3% post, adjusted odds ratio [aOR] 1.26, 95% CI 1.24–1.27), the HDP rate was significantly lower in the post-ARRIVE group among patients undergoing induction at 39 weeks of gestation (14.7% pre vs 14.1% post, aOR 0.91, 95% CI 0.90–0.93), decreasing by 12.0% per year (P<.001). The rate of HDP among all other delivering patients was higher in the post-ARRIVE group (4.1% pre vs 5.5% post, aOR1.32, 95% CI 1.30–1.34). Our findings may suggest that, as the overall HDP rate rises, the relative advantage of 39-week induction will rise similarly.

show abstract

Section: Discussionsupporting

confidence: 84%

mentioning

confidence: 99%

Changes in Rates of Hypertensive Disorders of Pregnancy Among Nulliparous Patients After the ARRIVE (A Randomized Trial of Induction Versus Expectant Management) Trial

Futterman

Gilroy

Silver

et al. 2023

Obstetrics &Amp; Gynecology

View full text Add to dashboard Cite

show abstract

“…HDP are a constellation of diseases (including preeclampsia, eclampsia, and gestational hypertension, as well as hemolysis, elevated liver enzymes, and low platelet count syndrome) and account for high BP during the peripartum period. The prevalence increased from 2.79% in 1989 to 8.22% in 2020, and these disorders account for 7.4% of pregnancy-related deaths 83 . Preeclampsia remains one of the leading causes of global maternal and perinatal morbidity and mortality, especially in resource-constrained countries 84 …”

Section: Resuscitation In Hdpmentioning

confidence: 99%

Resuscitation in obstetric care

Brennan,

Angelidis

2023

International Anesthesiology Clinics

View full text Add to dashboard Cite

“…Furthermore, it causes fetal growth retardation, premature birth and perinatal stillborn fetus ( Al Khalaf et al, 2022 ). Current evidence suggests that PIH is a significant threat to more than 70,000 gravidas and half a million fetuses worldwide yearly, with a high maternal mortality rate ranging from 10 to 16% ( Bruno et al, 2022 ).…”

Section: Introductionmentioning

confidence: 99%

Exploring the mechanism of Alisma orientale for the treatment of pregnancy induced hypertension and potential hepato-nephrotoxicity by using network pharmacology, network toxicology, molecular docking and molecular dynamics simulation

Liao

Ding

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

Background: Pregnancy-induced Hypertension (PIH) is a disease that causes serious maternal and fetal morbidity and mortality. Alisma Orientale (AO) has a long history of use as traditional Chinese medicine therapy for PIH. This study explores its potential mechanism and biosafety based on network pharmacology, network toxicology, molecular docking and molecular dynamics simulation.Methods: Compounds of AO were screened in TCMSP, TCM-ID, TCM@Taiwan, BATMAN, TOXNET and CTD database; PharmMapper and SwissTargetPrediction, GeneCards, DisGeNET and OMIM databases were used to predict the targets of AO anti-PIH. The protein-protein interaction analysis and the KEGG/GO enrichment analysis were applied by STRING and Metascape databases, respectively. Then, we constructed the “herb-compound-target-pathway-disease” map in Cytoscape software to show the core regulatory network. Finally, molecular docking and molecular dynamics simulation were applied to analyze binding affinity and reliability. The same procedure was conducted for network toxicology to illustrate the mechanisms of AO hepatotoxicity and nephrotoxicity.Results: 29 compounds with 78 potential targets associated with the therapeutic effect of AO on PIH, 10 compounds with 117 and 111 targets associated with AO induced hepatotoxicity and nephrotoxicity were obtained, respectively. The PPI network analysis showed that core therapeutic targets were IGF, MAPK1, AKT1 and EGFR, while PPARG and TNF were toxicity-related targets. Besides, GO/KEGG enrichment analysis showed that AO might modulate the PI3K-AKT and MAPK pathways in treating PIH and mainly interfere with the lipid and atherosclerosis pathways to induce liver and kidney injury. The “herb-compound-target-pathway-disease” network showed that triterpenoids were the main therapeutic compounds, such as Alisol B 23-Acetate and Alisol C, while emodin was the main toxic compounds. The results of molecular docking and molecular dynamics simulation also showed good binding affinity between core compounds and targets.Conclusion: This research illustrated the mechanism underlying the therapeutic effects of AO against PIH and AO induced hepato-nephrotoxicity. However, further experimental verification is warranted for optimal use of AO during clinical practice.

show abstract

Trends in Hypertensive Disorders of Pregnancy in the United States From 1989 to 2020

Abstract: From 1989 to 2020, the nationwide incidence of hypertensive disorders of pregnancy and chronic hypertension increased whereas the rate of eclampsia nearly halved.

Cited by 24 publications

References 6 publications

Changes in Rates of Hypertensive Disorders of Pregnancy Among Nulliparous Patients After the ARRIVE (A Randomized Trial of Induction Versus Expectant Management) Trial

Changes in Rates of Hypertensive Disorders of Pregnancy Among Nulliparous Patients After the ARRIVE (A Randomized Trial of Induction Versus Expectant Management) Trial

Resuscitation in obstetric care

Exploring the mechanism of Alisma orientale for the treatment of pregnancy induced hypertension and potential hepato-nephrotoxicity by using network pharmacology, network toxicology, molecular docking and molecular dynamics simulation

Contact Info

Product

Resources

About